Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

[Primary and Secondary Prevention of Hip Fragility Fracture in Teruel Health Sector, Aragon, Spain].

Gómez Navarro R, González García P, Martín Hernández C, Castro Sauras Á, Valdearcos Enguídanos S.

Rev Esp Salud Publica. 2017 Jan 2;91. pii: e201701002. Spanish.

2.

AI-related BMD variation in actual practice conditions: A prospective cohort study.

Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X.

Endocr Relat Cancer. 2016 Apr;23(4):303-12. doi: 10.1530/ERC-16-0025.

PMID:
26911377
3.

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.

Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S.

Osteoporos Int. 2015 Jun;26(6):1857-64. doi: 10.1007/s00198-015-3100-7.

4.

The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial.

Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, Shikany JM, Raiesdana A, Heckbert SR, Manson JE, LaCroix AZ, Siscovick D, Kestenbaum B, Smith NL, de Boer IH.

Thromb Haemost. 2015 May;113(5):999-1009. doi: 10.1160/TH14-05-0478.

PMID:
25672892
5.

Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment.

Willemse PM, Hamdy NA, de Kam ML, Burggraaf J, Osanto S.

J Clin Endocrinol Metab. 2014 Nov;99(11):4101-8. doi: 10.1210/jc.2014-1722.

PMID:
25119312
6.

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.

Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X.

7.

Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative.

Cauley JA, Chlebowski RT, Wactawski-Wende J, Robbins JA, Rodabough RJ, Chen Z, Johnson KC, O'Sullivan MJ, Jackson RD, Manson JE.

J Womens Health (Larchmt). 2013 Nov;22(11):915-29. doi: 10.1089/jwh.2013.4270.

8.

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.

Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35.

9.

Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.

Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM.

Osteoporos Int. 2013 Oct;24(10):2571-9. doi: 10.1007/s00198-013-2343-4.

PMID:
23563932
10.

Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study.

Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, Chlebowski RT, Manson JE, Van Horn L, Vitolins MZ, Datta M, LeBlanc ES, Cauley JA, Rossouw JE.

Osteoporos Int. 2013 Feb;24(2):567-80. doi: 10.1007/s00198-012-2224-2.

11.

Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes.

Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, Kritchevsky SB, Cauley JA, Tanaka T, Ferrucci L, Bandinelli S, Patel KV, Hagström E, Michaëlsson K, Melhus H, Wang T, Wolf M, Psaty BM, Siscovick D, Kestenbaum B.

JAMA. 2012 Nov 14;308(18):1898-905. doi: 10.1001/jama.2012.17304.

12.
13.

Summaries for patients: Vitamin D levels and risk for major clinical disease events.

[No authors listed]

Ann Intern Med. 2012 May 1;156(9):I36. doi: 10.7326/0003-4819-156-9-201205010-00001. No abstract available.

PMID:
22547485
14.

Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study.

de Boer IH, Levin G, Robinson-Cohen C, Biggs ML, Hoofnagle AN, Siscovick DS, Kestenbaum B.

Ann Intern Med. 2012 May 1;156(9):627-34. doi: 10.7326/0003-4819-156-9-201205010-00004.

15.

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

Sergi G, Pintore G, Falci C, Veronese N, Berton L, Perissinotto E, Basso U, Brunello A, Monfardini S, Manzato E, Coin A.

J Bone Miner Metab. 2012 Jul;30(4):461-7. doi: 10.1007/s00774-011-0341-1.

PMID:
22160398
16.
17.

Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set.

Bolland MJ, Grey A, Gamble GD, Reid IR.

Am J Clin Nutr. 2011 Oct;94(4):1144-9. doi: 10.3945/ajcn.111.015032.

18.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105.

PMID:
21807761
19.

Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.

Yang KH, Park SY, Park SW, Lee SH, Han SB, Jung WK, Kim SJ.

J Bone Miner Metab. 2010 Nov;28(6):713-8. doi: 10.1007/s00774-010-0203-2.

PMID:
20607326
20.

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.

J Clin Oncol. 2010 Feb 20;28(6):967-75. doi: 10.1200/JCO.2009.24.5902.

PMID:
20065185
Items per page

Supplemental Content

Loading ...
Support Center